1-propyl-1H-pyrrole | 5145-64-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯
• 英文名称: 1-propyl-1H-pyrrole
• 英文别名: N-propylpyrrole；1-Propyl-pyrrol；N-n-propylpyrrole；1H-Pyrrole, 1-propyl-；1-propylpyrrole
• CAS: 5145-64-2
• 化学式: C₇H₁₁N
• mdl: MFCD12187107
• 分子量: 109.171
• InChiKey: MFGOZCIHXVFZBC-UHFFFAOYSA-N

物化性质

• 熔点：
  1.5°C (estimate)
• 沸点：
  160.58°C (estimate)
• 密度：
  0.8833
• 保留指数：
  886;910;879;889

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  8
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.428
• 拓扑面积：
  4.9
• 氢给体数：
  0
• 氢受体数：
  0

安全信息

• 海关编码：
  2933990090

反应信息

• 作为反应物：
  描述：

  1-propyl-1H-pyrrole 在 钯 作用下， 生成 N-正丙基吡咯烷
  参考文献：
  名称：

  Jur'ew; Schenj'an, Zhurnal Obshchei Khimii, 1934, vol. 4, p. 1258,1260

  摘要：

  DOI：
• 作为产物：
  描述：

  N-正丙基吡咯烷 生成 1-propyl-1H-pyrrole
  参考文献：
  名称：

  Jur'ew; Schenj'an, Zhurnal Obshchei Khimii, 1934, vol. 4, p. 1258,1260

  摘要：

  DOI：

文献信息

• PYRROLOPYRAZINE-SPIROCYCLIC PIPERIDINE AMIDES AS MODULATORS OF ION CHANNELS
  申请人：Hadida Ruah Sara Sabina

  公开号：US20120196869A1

  公开（公告）日：2012-08-02

  The invention relates to pyrrolopyrazine-spirocyclic piperidine amide compounds useful as inhibitors of ion channels. The invention also provides pharmaceutically acceptable compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various disorders.

  这项发明涉及对离子通道具有抑制作用的吡咯吡嘧啶-螺环哌啶酰胺化合物。该发明还提供了包括该发明化合物的药学上可接受的组合物，以及使用这些组合物治疗各种疾病的方法。
• [EN] ETHYNE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF<br/>[FR] DÉRIVÉS D'ÉTHYNE, COMPOSITIONS PHARMACEUTIQUES ET LEURS UTILISATIONS
  申请人：BOEHRINGER INGELHEIM INT

  公开号：WO2012032014A1

  公开（公告）日：2012-03-15

  invention relates to new compounds of the formula I to their use as medicaments, to methods for their therapeutic use and to pharmaceutical compositions containing them.

  这项发明涉及公式I的新化合物，涉及它们作为药物的用途，涉及它们的治疗用途的方法，以及含有它们的药物组合物。
• "Growth from surface" Methodology for the Fabrication of Functional Dual Phase Conducting Polymer polypyrrole/polycarbazole/Polythiophene (CP/polyPyr/polyCbz/PolyTh)-Carbon Nanotube (CNT) Composites of Controlled Morphology and Composition - Sidewall versus End-Selective PolyTh Deposition
  申请人：Lellouche Jean-Paul

  公开号：US20130040049A1

  公开（公告）日：2013-02-14

  A “growth from the surface” method for selectively depositing oxidative Liquid Phase Polymerizations (LPPs) onto the carbon nanotube (CNT) surface, said method comprising steps of: a. obtaining Multi-walled Carbon Nanotubes (MWC-NT); b. oxidized said MWCNTs to obtain oxidized COOH-MWCNTs; thereby (a) carboxylative opening oxidation-sensitive end-caps (polyCOOH end cluster); and, (b) introducing defect carboxylic (COOH) groups onto predetermined areas of said oxidized COOH-MWCNTs; c. COOH activating the polyCOOH shell using various COOH activating species; and, d. executing Liquid Phase Polymerization (LPP) oxidative depositing polymers selected from said polyCOOH polyTh-CP polymers, polyCOOH poly-Th-, polyEDOT (PEDOT)-, polyTh polyCOOH poly(thiophenyl-3 acetic acid, thiophenyl-3 acetic acid/EDOT, polyX, wherein X is elected from COOH, OH, NH2, polyCbz/polyPyr CP polymers and related combinatorial mixtures, polyCOOH PEDOT-poly(thiophenyl-3 acetic acid)′ thereby selectively depositing said oxidative LPPs onto said CNT surface.

  一种用于选择性沉积氧化液相聚合物（LPPs）到碳纳米管（CNT）表面的“从表面生长”方法，所述方法包括以下步骤：a. 获得多壁碳纳米管（MWC-NT）；b. 氧化所述MWCNTs以获得氧化的COOH-MWCNTs；从而（a）羧化开启氧化敏感端盖（polyCOOH端簇）；以及（b）在所述氧化的COOH-MWCNTs的预定区域引入缺陷羧基（COOH）基团；c. 使用各种COOH活化物种对polyCOOH壳进行COOH活化；以及d. 执行液相聚合物化学氧化沉积聚合物，所选聚合物来自所述polyCOOH polyTh-CP聚合物，polyCOOH poly-Th-，polyEDOT（PEDOT）-，polyTh polyCOOH poly（噻吩-3 乙酸，噻吩-3 乙酸/EDOT，polyX，其中X选自COOH，OH，NH2，polyCbz/polyPyr CP聚合物和相关组合物，polyCOOH PEDOT-poly（噻吩-3 乙酸）'，从而选择性地将所述氧化LPPs沉积到所述CNT表面。
• Radical Cycloaddition by Nickel(II) Complex-Catalyzed Electroreduction. A Method for Preparation of Pyrrolopyridine and Pyrrolopyrrole Derivatives.
  作者：Shigeko OZAKI、Shizue MITOH、Hidenobu OHMORI

  DOI：10.1248/cpb.44.2020

  日期：——

  Cycloalkano[α]pyrroles were obtained by reductive radical cycloaddition of 1-(2-iodoethyl)pyrrole and activated olefins or by cyclization of 1-(ω-iodoalkyl)pyrroles, through electroreduction of the iodides using nickel(II) complex as an electron-transfer catalyst.

  环烷基[α]吡咯是通过1-(2-碘乙基)吡咯与活化烯烃的还原自由基环加成反应，或通过对1-(ω-碘烷基)吡咯的环化反应而获得的，采用镍(II)络合物作为电子转移催化剂对碘化物进行电还原。
• MACROCYCLIC ANTAGONISTS OF THE MOTILIN RECEPTOR FOR TREATMENT OF GASTROINTESTINAL DYSMOTILITY DISORDERS
  申请人：Marsault Eric

  公开号：US20100093720A1

  公开（公告）日：2010-04-15

  The present invention provides conformationally-defined macrocyclic compounds that bind to and/or are functional modulators of the motilin receptor including subtypes, isoforms and/or variants thereof. These macrocyclic compounds, at a minimum, possess adequate pharmacological properties to be useful as therapeutics for a range of disease indications. In particular, these compounds are useful for treatment and prevention of disorders characterized by hypermotilinemia and/or gastrointestinal hypermotility, including, but not limited to, diarrhea, cancer treatment-related diarrhea, cancer-induced diarrhea, chemotherapy-induced diarrhea, radiation enteritis, radiation-induced diarrhea, stress-induced diarrhea, chronic diarrhea, AIDS-related diarrhea, C. difficile associated diarrhea, traveller's diarrhea, diarrhea induced by graph versus host disease, other types of diarrhea, dyspepsia, irritable bowel syndrome, chemotherapy-induced nausea and vomiting (emesis) and post-operative nausea and vomiting and functional gastrointestinal disorders. In addition, the compounds possess utility for the treatment of diseases and disorders characterized by poor stomach or intestinal absorption, such as short bowel syndrome, celiac disease and cachexia. The compounds also have use for the treatment of inflammatory diseases and disorders of the gastrointestinal tract, such as inflammatory bowel disease, ulcerative colitis, Crohn's disease and pancreatitis. Accordingly, methods of treating such disorders and pharmaceutical compositions including compounds of the present invention are also provided.

  本发明提供了与胃动素受体及其亚型、异构体和/或变体结合和/或是功能调节剂的构象定义明确的大环化合物。这些大环化合物至少具有足够的药理特性，可用作治疗一系列疾病指示的治疗药物。特别是，这些化合物对于治疗和预防以高胃动素血症和/或胃肠道高蠕动性为特征的疾病非常有用，包括但不限于腹泻、癌症治疗相关腹泻、癌症诱导腹泻、化疗诱导腹泻、放射性肠炎、放射性腹泻、压力诱导腹泻、慢性腹泻、艾滋病相关腹泻、C. difficile相关腹泻、旅行者腹泻、移植物宿主病引起的腹泻、其他类型的腹泻、消化不良、肠易激综合征、化疗诱导的恶心和呕吐（呕吐）以及术后恶心和呕吐和功能性胃肠道疾病。此外，这些化合物对于治疗以胃或肠道吸收不良为特征的疾病和疾病也具有用途，例如短肠综合征、乳糜泻和虚弱。这些化合物还可用于治疗胃肠道炎症性疾病和疾病，如炎症性肠病、溃疡性结肠炎、克罗恩病和胰腺炎。因此，本发明还提供了治疗此类疾病的方法和包括本发明化合物的药物组合物。